



SESSION 1 October 3	All Times are listed in PACIFIC TIME
8:00 am	Opening Comments and Pre-Test
8:15 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease Liver Transplantation <ul style="list-style-type: none"> • Listing criteria, MELD scores, Exceptions and the transplant process Case Study 1 – Cirrhosis and Encephalopathy
9:15 am	Hepatology Update I – Viral Hepatitis <ul style="list-style-type: none"> • The reemergence of Hepatitis A and Transplanting HCV+ organs to HCV- recipients
9:40 am	Intermission Presentation
10:15 am	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology, Demographics and Diagnosis • Treatment options for thrombocytopenia; including alternatives to platelet transfusion • Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease
10:50 am	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH • Lifestyle changes as a therapy • Drugs in clinical development for NASH Case Study 2 - NASH Diagnosis and Treatment
11:45 am	Adjourn
SESSION 2 October 10	
8:00pm	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis <ul style="list-style-type: none"> • Epidemiology of PSC Predicting outcomes and Improving Survival in PSC patients • Causes and Markers of PBC • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid •
8:40 am	Hepatology Update II - Current/Emerging Topics in Liver Disease <ul style="list-style-type: none"> • Alcoholic Liver Disease and Hepatorenal Syndrome,
9:00 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery
9:35 am	Intermission Presentation And Stretch Break
10:10 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC Case Study 3 – Diagnosis and Treatment of Hepatocellular Carcinoma
11:00 am	Post-test and Wrap-Up
11:15 am	Adjourn

Course Directors: Paul J. Pockros, MD - Scripps Clinic
Catherine Frenette, MD – Scripps Center for Cell and Organ Transplantation

Peer Review: Luis Marsano, MD- University of Louisville School of Medicine